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PD1-1:
REST MODULATES HYPOXIA-INDUCED NEUROENDOCRINE
DIFFERENTIATION OF PROSTATE CANCER CELLS BY ACTIVATING
AUTOPHAGY SIGNALING
Tzu-Ping Lin 1,2, Yi-Ting Chang 3, Sung-Yuan Lee 3, Pei-Ching
Chang 3. 1Department of Urology, Taipei Veterans General Hospital, Taipei,
Taiwan; 2Department of Urology, School of Medicine, and Shu-Tien
Urological Research Center, National Yang-Ming University, Taipei, Taiwan;
3 Institute of Microbiology and Immunology, National Yang-Ming University,
Taipei, Taiwan
Purpose: To study the role of element-1 silencing transcription factor(R-
EST) in hypoxia induced neuroendocrine differentiation(NED) of prostate
cancer.
Materials and Methods: Prostate cancer cell line LNCaP was cultured in
hypoxic chamber to induce NED. Neuroendocrine differentiation was quan-
tiﬁed by neurite length measurement by phase-contrast optical microscope.
Inducible REST knock down and overexpression LNCaP cell line was estab-
lished and used to determine the effect of REST in NED in LNCaP cells. RNA
was harvested from hypoxia-treated LNCaP, normoxia LNCaP, induced REST
knock down LNCaP cells and sequenced with Illumina Genome AnalyzerII.
Results: REST, a transcriptional repressor of neuronal genes that has been
implicated in androgen-deprivation and IL-6 induced NED, is essential for
hypoxia-induced NED of PCa cells. Bioinformatics analysis of transcriptome
proﬁle of REST knockdown with hypoxia treatment demonstrated that
REST is a master regulator of hypoxia-induced genes. Gene set enrichment
analysis (GSEA) of hypoxia and REST knockdown co-upregulated genes
revealed their correlation with HRPC. Consistently, gene ontology (GO)
analysis showed that REST reduction potential associated with hypoxia-
induced tumorigenesis, NE development, and AMPK pathway activation.
Conclusion: REST knockdown alone is capable of activating AMPK and
autophagy activation is essential for hypoxia-induced NED of PCa cells.
PD1-2:
INHIBITION OF CISPLATIN-INDUCED AUTOPHAGY ENHANCES
APOPTOTIC CELL DEATH IN HUMAN BLADDER CANCER CELLS
Thomas I-Sheng Hwang 1,2,3,4, Ji-Fan Lin 5, Yi-Chia Lin 1, Te-Fu Tsai 1, Hung-
En Chen 1, Kuang-Yu Chou 1. lDepartment of Surgery, Shin Kong Wu Ho-Su
Memorial Hospital, Taipei, Taiwan; 2Department of Urology, Shin Kong Wu
Ho-Su Memorial Hospital, Taipei, Taiwan; 3Department of Urology, Taipei
Medical University, Taipei, Taiwan; 4Division of Urology, School of
Medicine, Fu-Jen Catholic University, Taipei, Taiwan; 5Central Laboratory,
Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
Purpose: Bladder cancer (BC) is a common urologic cancer with high
recurrence rate. Cisplatin is the ﬁrst member of a class of platinum-con-
taining anti-cancer drugs that binding to and causing DNA cross-linking
which ultimately leads to apoptosis. Cisplatin is used to treat various types of
cancers including BC. However, cisplatin alone is not very effective in BC and1879-5226/ Copyright © 2015, Taiwan Urological Association. Published by Elsevier Ta
creativecommons.org/licenses/by-nc-nd/4.0/).the combinations of gemcitabine/cisplatin is now the ﬁrst-line chemo-
therapy for muscle invasive BC. Our previous studies showed that BC cells
exhibits high basal level of autophagy and treatment of chemotherapeutic
agents further induces autophagy as a survival mechanism. In this study, we
investigated if cisplatin induces autophagy in human BC cells and whether
inhibition of cisplatin-induced autophagy enhances cancer cell death.
Materials and Methods: The cell viability of RT4 (grade I), 5637 (grade II),
and T24 (grade III) humanbladder cancer cells treatedwith cisplatin alone or
combinedwith autophagy inhibitor, baﬁlomycinA1 (BafA1),was accessedby
WST-8 cell viability kit. The autophagy status in cells was performed by the
detection of microtubule-associated light chain 3 form II (LC3-II) using
immunoﬂuorescent staining and Western blot. Moreover, the formation of
autophagolysosomewasdetectedusing transmission electronmicroscopy to
conﬁrm the induction of autophagy in cisplatin-treated T24 cells. To inves-
tigate the signaling pathway involved in cisplatin-induced autophagy, the
activation of AKT, ERK, AMPK and MAPK and the inhibition of mTOR in
cisplatin-treated cells were detected using Western blot. Induced apoptosis
was determined by the detection of cleavage caspase 3, and the measure-
ment of caspase 3/7 activity and DNA fragmentation in treated-cells.
Results: Advanced bladder cancer cells (5637 and T24) were more resis-
tant to cisplatin than RT4. The processing of LC3-II was elevated in cells
treated with increased concentration of cisplatin, suggesting cisplatin in-
duces autophagy. Detection of autophagy ﬂux by blocking autophgosome
to lysosomes fusion using Baf A1 and the direct observation of autopha-
golysosome formation in cisplatin-treated T24 cells using TEM further
conﬁrmed that cisplatin indeed triggers autophagy in BC cells. Activation
of AKT, ERK and MAPK signaling and inhibition of mTOR was detected in
cisplatin treated cells. However, pretreatment of speciﬁc inhibitors of ERK,
MAPK did not attenuated cisplatin-induced autophagy suggests these
pathways are not involved in the induction of autophagy. Finally, reduced
cell viability and induced apoptosis were observed in cisplatin-treated
cells pretreated with autophagy inhibitor suggesting that inhibition of
autophagy enhances cancer killing effect of cisplatin in human BC cells.
Conclusion: Cisplatin induces autophagy through activation of AKT and
inhibition of mTOR in human BC cells. Our data suggest that autophagy
inhibition promotes apoptosis in cisplatin-treated cells, and could be a
new therapeutic paradigm for the treatment of bladder cancer.
PD1-3:
NOVEL BLADDER CANCER BIOMARKERS DISCOVERY BY
MICRODISSECTED COMPARATIVE TISSUE PROTEOMICS
Chien-Lun Chen, Ting Chung, Chih-Ching Wu, Kwai-Fong Ng, Jau-Song
Yu, Cheng-Han Tsai, Yu-Sun Chang, Ying Liang, Ke-Hung Tsui, Yi-Ting
Chen. Department of Urology, Chang Gung Memorial Hospital, Linko Chang
Gung University, Taoyuan, Taiwan
Purpose: More than 380,000 new cases of bladder cancer are diagnosed
worldwide, accounting for 150,200 deaths each year. No reliable biomarker
for bladder cancer is used clinically. We employed a strategy combining
laser microdissection, isobaric tags for relative and absolute quantitation
labeling, and liquid chromatography-tandem MS (LC-MS/MS) analysis to
proﬁle proteomic changes in fresh-frozen bladder tumor specimens.iwan LLC. This is an open access article under the CC BY-NC-ND license (http://
